AC Immune
Financials
Estimates*
| CHF | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 15.4m | - | 3.9m | 14.8m | 5.1m | 67.5m | 66.1m |
| % growth | (86 %) | - | - | 276 % | (66 %) | 1231 % | (2 %) |
| EBITDA | (59.2m) | (70.1m) | (70.8m) | (50.4m) | (77.9m) | 33.2m | (79.2m) |
| % EBITDA margin | (384 %) | - | (1799 %) | (340 %) | (1537 %) | 49 % | (120 %) |
| Profit | (61.9m) | (73.0m) | (70.8m) | (54.2m) | (78.7m) | (22.9m) | (29.9m) |
| % profit margin | (401 %) | - | (1798 %) | (366 %) | (1553 %) | (34 %) | (45 %) |
| EV / revenue | 22.8x | - | 37.0x | 28.1x | 28.1x | 2.8x | 4.0x |
| EV / EBITDA | -5.9x | -6.0x | -2.1x | -8.3x | -1.8x | 5.7x | -3.3x |
| R&D budget | 59.5m | 62.3m | 60.3m | 54.6m | - | - | - |
| R&D % of revenue | 386 % | - | 1533 % | 369 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €19.0m | Series B | |
| N/A | $34.6m | Series C | |
€18.0m | Series D | ||
* | €39.6m | Series E | |
| N/A | $58.0m Valuation: $652m | IPO | |
$25.0m | Private Placement VC | ||
* | $50.1m | Post IPO Equity | |
| Total Funding | $144m | ||
Related Content
Recent News about AC Immune
EditAC Immune is a biopharmaceutical company specializing in the development of innovative therapies and diagnostics for neurodegenerative diseases, such as Alzheimer's and Parkinson's. The company operates in the biotechnology sector and primarily serves patients, healthcare providers, and pharmaceutical companies. AC Immune's business model revolves around leveraging its proprietary technology platforms to create a broad pipeline of products aimed at treating and diagnosing neurodegenerative conditions. The company generates revenue through partnerships, licensing agreements, and milestone payments from larger pharmaceutical firms. AC Immune's goal is to become a global leader in precision medicine for neurodegenerative diseases, addressing one of the most significant challenges facing society today.
Keywords: biopharmaceutical, neurodegenerative, Alzheimer's, Parkinson's, diagnostics, therapies, biotechnology, proprietary technology, precision medicine, healthcare.